These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 22265683)

  • 1. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Angelico F; Del Ben M; Pignatelli P; Violi F
    Dig Liver Dis; 2013 Jan; 45(1):81-2. PubMed ID: 22917635
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Dig Liver Dis; 2013 Jan; 45(1):82-3. PubMed ID: 23058851
    [No Abstract]   [Full Text] [Related]  

  • 5. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Yamagishi S
    Dig Liver Dis; 2013 Jan; 45(1):82. PubMed ID: 22909420
    [No Abstract]   [Full Text] [Related]  

  • 6. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Yamagishi S; Maeda S; Hyogo H
    Dig Liver Dis; 2013 Jan; 45(1):83-4. PubMed ID: 23099228
    [No Abstract]   [Full Text] [Related]  

  • 7. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
    Preston RA; Harvey P; Herfert O; Dykstra G; Jukema JW; Sun F; Gillen D
    J Clin Pharmacol; 2007 Dec; 47(12):1555-69. PubMed ID: 18048574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
    Abel T; Fehér J; Dinya E; Gamal Eldin M; Kovács A
    Orv Hetil; 2009 May; 150(21):989-93. PubMed ID: 19443308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
    Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2010 Dec; 61(6):705-10. PubMed ID: 21224501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
    Kosmidou MS; Hatzitolios AI; Adamidou A; Giannopoulos S; Raikos N; Parharidis G; Milionis HJ
    Am J Hypertens; 2008 Mar; 21(3):303-9. PubMed ID: 18202666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
    Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.